Working… Menu

The Lymphoid Tissue Pharmacology of Antiretroviral Drugs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02707926
Recruitment Status : Not yet recruiting
First Posted : March 14, 2016
Last Update Posted : October 23, 2018
University of Minnesota - Clinical and Translational Science Institute
Information provided by (Responsible Party):
Courtney Fletcher, University of Nebraska

Brief Summary:


Antiretroviral drugs (ARVs) with enhanced LT penetration characteristics in vitro and in macaques will translate into an ARV regimen with increased LN and GALT concentrations and a faster decay and more potent suppression of HIV replication in LT in HIV-infected persons.


  1. Determine lymph nodes (LN) and gut-associated lymphoid tissue (GALT) pharmacokinetics (PK) in HIV-infected persons on an antiretroviral drug (ARV) regimen.
  2. Determine virological responses of antiretroviral therapy in plasma, peripheral blood mononuclear cells (PBMCs) and lymphoid tissue (LT).

Condition or disease Intervention/treatment
HIV Infection Drug: Anti-HIV Agents

Detailed Description:

This is a single-center study of 18 ARV naïve, HIV infected persons to assess impact of an ARV regimen on lymph node (LN) and (GALT) virus reservoirs.

All participants will give informed consent. At baseline, plasma and PBMCs will be obtained and all subjects will have an incisional biopsy of an inguinal LN and pinch biopsy of ileum and rectum via colonoscopy. The selected LT-enhanced ARV regimen will be initiated. Participants will return to the clinic at weeks 2 and 4 and then monthly for safety evaluations, CD4 T cell counts, plasma HIV-RNA and ARV drug concentrations in plasma and PBMCs. An intensive PK study will be performed at week 2. At months 3 and 6, the inguinal LN biopsy and pinch biopsies of ileum and rectum will be repeated.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 18 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Lymphoid Tissue Pharmacology of Antiretroviral Drugs
Estimated Study Start Date : October 2019
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Intervention Details:
  • Drug: Anti-HIV Agents
    Therapy to treat HIV infection

Primary Outcome Measures :
  1. Ratio of antiretroviral drug concentration in lymph node (LN) to peripheral blood mononuclear cells (PBMCs) [ Time Frame: 6 months ]
  2. Lymph node (LN) residual viremia. [ Time Frame: 6 months ]
    Quantification of residual viremia in lymph node (LN) at 6 months of therapy as measured by digital droplet polymerase chain reaction (PCR), which can quantify as low as 50 copies/million cells.

Biospecimen Retention:   Samples Without DNA
Blood, urine, lymph node biopsy, colonoscopy biopsy of ileum and rectum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eighteen (18) antiretroviral drug (ARV)-naive, HIV-infected persons who are going to initiate ARV therapy will be recruited at the University of Minnesota. Study entry is open to adults regardless of race or ethnic background. While there will be every effort to seek out and include minority participants from both genders, the patient population is expected to be no different than that of the HIV infected population in Minnesota.

Inclusion Criteria:

  1. Antiretroviral drug (ARV)-naive, HIV-infected individuals
  2. Aged 18 years or over
  3. Agree to initiating ARV therapy
  4. BMI ≤ 30
  5. Inguinal lymph node(s) identifiable by ultrasound at enrollment
  6. Screening plasma HIV RNA > 40,000 copies/mL
  7. Screening CD4 count > 200 cells/mm3
  8. Women of child bearing potential must agree to use effective contraception while on the study.
  9. Screening viral isolates demonstrate genotype sensitivity to chosen antiretroviral therapy (ART) regimen.
  10. Able to provide voluntary written consent

Exclusion Criteria:

  1. Previous ARV therapy
  2. Contraindications to ARV regimen (e.g., comorbid conditions or drug interactions), or study procedures as determined by the principal investigator.
  3. Planning or current pregnancy or breastfeeding
  4. History and/or presence of any clinically significant disease or disorder, such as cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal and psychiatric/mental disease/disorder, which, in the opinion of the enrolling physician, may put the participant at risk because of participation in the study, influence the results of the study, or affect the participant's ability to participate in the study.
  5. Inability to comply with study procedures per enrolling physician discretion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02707926

Layout table for location contacts
Contact: Ann Thorkelson, MN, RN 612-625-7472
Contact: Tim Schacker, MD 612-624-9955

Sponsors and Collaborators
University of Nebraska
University of Minnesota - Clinical and Translational Science Institute
Layout table for investigator information
Principal Investigator: Tim Schacker, MD University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: Courtney V Fletcher, PharmD University of Nebraska

Layout table for additonal information
Responsible Party: Courtney Fletcher, Dean and Professor, University of Nebraska Identifier: NCT02707926     History of Changes
Other Study ID Numbers: 1601M83126
First Posted: March 14, 2016    Key Record Dates
Last Update Posted: October 23, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The results of this trial will be of interest to the HIV research and medical communities. We expect to submit the data from the main analysis within 6 months of completing the work. We will publish the results in a major scientific journal and present the results at a major scientific meeting (e.g., CROI). Subsequent analyses will be presented at national and international HIV meetings. Data generated under this project, and any intellectual property, will be administered in accordance with NIH policies, including the NIH Data Sharing Policy the NIH Public Access Policy.
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents